Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future

por Whiteman, David AH, Kimura, Alan
Publicado 2017

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)

por Pano, Arian, Barbier, Ann J, Bielefeld, Bonnie, Whiteman, David AH, Amato, David A
Publicado 2015

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy

por Giugliani, Roberto, Hwu, Wuh-Liang, Tylki-Szymanska, Anna, Whiteman, David A.H., Pano, Arian
Publicado 2014